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Introduction
With technical advances in computed tomography (CT) 
technology, the growing use of multi-row detector CT and 
the diffusion of screening programs, we have observed a 
dramatic increase in the identification of small pulmonary 
lesion (1,2). Moreover, in the era of personalized medicine, 
the mutational pattern acquired great importance in the 
therapeutic strategy for lung cancer (3). The cytohistologic 
identification of these undetermined nodules, especially 
if small, could be a difficult step in the management of 
patients with suspected lung cancer. On the other hand, 
whether early detection of small malignant nodules could 
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comprised ASA 3, FEV1 <70% of predicted, cardiac comorbidity or previous chest surgery. FNAB diagnostic 
performance and clinical efficacy were calculated.
Results: Out of 225 patients referred for FNAB, 68 covered inclusion criteria. Forty-nine out of 68 smears 
(72%) were adequate for diagnosis. Specificity was 100% (95% CI: 77–100%), sensitivity was 100% (95% 
CI: 90–100%). Positive and negative predictive values were 1.0 (95% CI: 0.9–1.0) and 1.0 (95% CI: 0.77–1.0) 
respectively. A post-biopsy pneumothorax was detected in 27 cases (39%); the pneumothorax rate was 
significantly affected by the number of passages (P=0.01).
Conclusions: The satisfactory results of our study lead to reconsidering FNAB in patients with pulmonary 
nodules below 15 mm in diameter, especially in order to avoid unnecessary surgery. 
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lead to a potentially curative surgical treatment, it is 
relevant to avoid unnecessary operations in the case of 
benign nodules (4,5).
CT-guided transthoracic fine needle aspiration biopsy 
(FNAB) is an established and safe technique for the 
diagnosis of intrathoracic lesions with a reported sensitivity 
that ranges from 74% to 95%, and a specificity between 
87% and 100% (6-9). Several studies demonstrated that cell 
blocks (CBs) derived from FNAB can also provide sufficient 
material for the molecular profiling, such as EGFR mutation 
and ALK gene rearrangement tests, which are mandatory 
for the therapeutic choice in lung adenocarcinoma (10-12). 
Thanks to the advances of the molecular techniques, which 
enable the identification of wide spectrum of mutations 
also using scant tissues, cytological specimens can represent 
the biologic source for molecular testing, avoiding further 
invasive procedures (13).
Few studies have been published regarding the diagnostic 
performance and complication prevalence of FNAB in the 
evaluation of small lung nodules (<20 mm). These studies 
reported that the diagnostic accuracy tends to decrease 
with the size of the lesions, and that the prevalence of 
complications, such as pneumothorax and chest tube 
placement, tends to rise as the size of lesion decreases 
(7-9,14-16). 
The aim of this study was to determine the accuracy and 
the diagnostic value of FNAB of solitary pulmonary nodules 
under 15 mm in diameter, in high risk patients.
Methods
This was an observational, retrospective, single-centre, 
cohort study conducted at Ca’ Granda Foundation 
University Hospital in Milan. The medical records of 
patients who were referred to our institution from January 
2012 to December 2014 were reviewed.
Inclusion criteria were patients with SPN ≤15 mm in 
diameter and American Society of Anesthesiologists (ASA) 
status III, previous chest surgery (lung resections) who 
required cytological assessment with FNAB. Nodules with 
diameter of 3 cm or less, single, spherical, well-circumscribed, 
and surrounded by aerated lung were considered SPN 
(1,2,17). Study end-points were FNAB adequacy, diagnostic 
accuracy, complications prevalence and clinical value.
All biopsies were performed according to a standard 
protocol after a multidisciplinary evaluation by thoracic 
surgeons, oncologists and pathologists. Patients were 
previously instructed to discontinue anticoagulation 
therapy if they took it routinely. CT and PET scans, 
routinely performed before multidisciplinary evaluation, 
were reviewed immediately before the procedure. All 
FNABs were performed by a thoracic surgeon with large 
experience (Dr Tosi D). Informed consent was obtained 
from all patients before the procedure. The SPN diameter, 
its location (peripheral, mid-lobar or hilar), and the clinical 
outcome were extracted from patients’ charts. 
At the time of biopsy, spiral CT scan was performed 
through the area of interest setting a slice thickness of 
5 mm. The patient was then positioned on the CT table 
according to the best position for biopsy. Skin entry point 
was marked with a metallic marker and 10 mL of 2% 
lidocaine were administered to induce local anesthesia. 
Twenty-three Gauge Chiba needles were used in majority 
of the cases, but in case of lesions close to the chest wall, 
22 Gauge needles were preferred, because of the limited 
risk of pneumothorax. The length of the needle was chosen 
according to the distance of the lesion from the chest 
wall. A step by step progression of the needle tip was then 
confirmed by CT scan (Figure 1). After confirmation of 
adequate position of the needle tip, aspirates were obtained; 
a part of the material was settled up with MGG (May-
Grunwald-Giemsa) stain and submitted to a cytopathologist 
with experience in pulmonary pathology, in order to have 
a rapid on-site evaluation (ROSE). If the specimen was 
considered adequate, the procedure ended, if not, the 
aspirations were repeated up to three times. 
A final CT scan of the region of interest was performed 
to exclude complications, in particular pneumothorax. 
Chest tube was inserted immediately under CT guide if the 
pneumothorax was large or if the patient was symptomatic; 
smaller asymptomatic pneumothorax was treated by placing 
Figure 1 Adenocarcinoma of the right lung. The fine needle is 
inserted in the right thorax under CT guide.
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the patient in a recumbent position. All patients had an 
expiration chest X-ray in erect position one hour after the 
FNAB, in order to exclude pneumothorax or hemorrhage. 
Patients without complications were subsequently 
discharged with detailed instructions about possible late 
symptoms, while a second chest X-ray was obtained after 
one hour in patients with radiographic evidence of small 
pneumothorax. If the pneumothorax was “large” at one-
hour chest X-ray, or when increasing pneumothorax 
has been documented on the second chest X-ray, the 
patients were treated with thoracostomy tube insertion. 
Symptomatic patients (shortness of breath, decreased 
oxygen saturation and substantial pain) had chest tube 
placement irrespectively to amount of pneumothorax (18).
The FNAB samples were fixed in formalin; samples 
were centrifuged in order to prepare paraffin blocks; 
immunohistochemistry was performed when an adequate 
specimen was available. According to well established 
criteria recommended by the World Health Organization 
(WHO 2004), the major histological criteria for adequate 
specimens are summarized.
(I) Squamous cell carcinomas: cohesive sheets and 
single cells with evidence of keratinization, 
Nucleus/Cytoplasm ratios range from low to high; 
dense, waxy, hard orangeophilic cytoplasm with 
clearly defined borders, cells with bizarre forms 
and hyperchromatic nuclei with inconspicuous or 
pyknotic nucleoli.
(II) Adenocarcinoma: cohesive sheets or clusters of cells 
with depth focus (three-dimensional); columnar, 
cuboidal, polygonal cells with scant/moderate 
cytoplasm with vacuolization, enlarged nuclei with 
prominent nucleoli.
(III) Small cell carcinoma: highly cellular aspirate 
with prominent coagulative necrosis and a high 
nucleus/cytoplasm ratio: very little cytoplasm and 
hyperchromatic nuclei with dispersed chromatin with 
a “salt and pepper” feature. In this subset of lesions, 
the research of neuroendocrine differentiation was 
performed with immunohistochemical analysis using 
the following antibodies: CD56, synaptophysin, and 
chromogranin A; furthermore, a proliferation index 
(Ki-67) was analyzed. 
All the mentioned criteria were taken into consideration 
by the cytopathologist in association with clinical-
instrumental data (anamnesis, radiological history, CT-PET), 
especially in patients with a low suspicion for malignancy.
The final cytological findings were classified positive for 
malignant tumor cells (MTC) or suspicious for malignancy. 
In this study MTC or “suspicious for malignancy” were 
considered as “positive” results. When there was evidence 
of a consistent cellular component but without any evidence 
of malignant tumor cells, the sample was recorded as 
negative for MTC; for the study aim, such findings were 
defined as a “negative” result after three punctures. We 
considered inadequate findings smears with insufficient 
or poor-quality cellular material from samples collected 
after three punctures. Patients with inadequate tests were 
submitted to surgical biopsy, repeated FNAB or clinical 
follow-up according to patients’ preference; such patients 
were excluded from the accuracy analysis (19,20).
Patients with positive results were considered for lung 
resection; patients with negative findings were followed 
up in order to exclude disease progression. After surgery, 
histological confirmation was obtained from formal fixed 
and paraffin embedded material when areas with squamous 
or glandular differentiation were observed. In poorly 
differentiated lesions, glandular differentiation was detected 
by TTF-1 and/or Napsin A immunohistochemical positivity 
as well as for P40 in squamous tumors or CD56 and/or 
synaptophysin for neuroendocrine differentiation.
Diagnostic accuracy was calculated by comparing the 
cytological diagnosis from the FNAB with findings obtained 
at surgical pathological examination or clinical follow-up.
Statistical analysis
Continuous data are presented as mean and standard 
deviation. Categorical variables are shown as numbers 
and percentages. Confidence interval for proportion was 
computed using normal approximation. Exact binomial 
confidence limits were calculated for sensitivity, specificity, 
and positive and negative predictive value (21). Confidence 
intervals for negative likelihood ratios were based on 
formulae provided by Simel (22). Chi square test was 
performed. Two-sided P values were computed. Statistical 
significance was considered when P value was equal or less 
than 0.05. Confidence interval was set at 95% confidence 
level. All analyses were carried out using R version 3.2.2 
software (23). 
Results
Out of 225 patients with SPN who were referred to our 
institution in the mentioned period, 68 matched the 
inclusion criteria. Demographics data are showed in Table 1. 
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Chiba needles with a size of 23 Gauge were used in 85% 
of cases. Nineteen procedures (28%) were inadequate 
for diagnosis; 49 procedures resulted adequate and were 
considered for diagnostic accuracy (72%; 95% CI: 60–82%).
Out of the 49 adequate results, 35 were positive for 
malignant tumor cells and 14 were negative (1 case: 
tuberculosis). Among the 35 positive cases, 12 nodules 
(34%) were classified as “suspicious for malignancy” or non-
small cell lung cancer (NSCLC), the remaining 23 cases had 
the histological type determined by immunohistochemistry: 
9 (25%) adenocarcinomas, 8 (22%) squamous cell 
carcinomas, 2 well differentiated neuroendocrine tumors, 
2 colorectal metastases, 1 uterine metastasis, and 1 bladder 
metastasis. Of the 35 cases positive for malignancy at 
FNAB, 33 patients had surgical confirmation (31 lung 
cancer and 2 pulmonary metastases). Two patients with 
lung metastases at FNAB findings were followed for more 
than 2 years with clinical confirmation; those patients were 
treated with chemotherapy or/and radiotherapy. Finally, 
out of the 49 adequate samples, 35 were recorded as true 
positives. Among the 14 negative cases, 5 nodules were 
specific benign lesions (4 granulomas, 1 hamartoma); 
in 4 cases inflammatory cells with a positive bacterial 
or mycobacterial culture were found. The remaining 
4 cases had a nonspecific benign cytology (macrophages, 
h is t iocytes ,  react ive  bronchia l  epi thel ium).  The 
14 patients with negative FNAB results were considered as 
true negative after follow-up without evidence of disease 
progression (median follow-up: 39 months; range, 25– 
59 months). Specificity was 100% (95% CI: 77–100%), 
sensitivity was 100% (95% CI: 90–100%). Diagnostic 
accuracy value was 100% (95% CI: 93–100%). Positive 
predictive value was 1.0 (95% CI: 0.9–1.0), negative 
predictive value was 1.0 (95% CI: 0.77–1.0). Number 
needed to diagnose was 1.0 (95% CI: 1.0–1.5). No 
differences were found, comparing the diagnostic accuracy 
for lesion size of 10 mm or less and for lesion size ranging 
from 11 to 15 mm (P>0.5). Regarding 19 patients with 
inadequate results from biopsy, every case was discussed 
during multidisciplinary team meetings, and submitted to 
surgical biopsy or radiologically followed up, depending on 
the clinical suspicious of malignancy.
The total overall number of punctures was 129; of 
them, 44 were the punctures in positive samples (mean: 
1.25/patient), 42 in negative samples (mean: 3/patient) 
and 43 in inadequate samples (mean 2.26/patient). In the 
group of malignant cases, a single aspirate was sufficient for 
diagnosis in 27 cases (77%), a second puncture was required 
in 7 cases (20%), a third in 1 (3%). 
The most frequent complication related to the FNAB 
procedure was pneumothorax, that occurred in 27 patients 
(39%, 95% CI: 28–52%); 19 patients required a chest 
drainage (28%). Pneumothorax occurrence and chest 
drain requirement were significantly associated with the 
number of punctures (P<0.001 and P<0.001, respectively). 
The association between respiratory comorbidities and 
pneumothorax rate is not statistically significant in our 
study. It is to underline that respiratory comorbidities, 
particularly emphysema is quite high in our cohort 
of patients (78%, as reported in Table 1), and this can 
be related to the lack of strong association. No other 
statistically significant risk factors were found; there was 
a trend of higher prevalence of pneumothorax rate in the 
group of patients with “inner third” lesions, but this wasn’t 
statistically significant, probably due to the small size of 
such subgroup.  
There was one case of hemoptysis, with spontaneous 
Table 1 Demographics data
Variables Value
Age, years, median [range] 65 [35–75]
Gender, male, n (%) 29 (42.6)
Lesion size, cm, median (range) 1.05 (0.5–1.5)
Body mass index, median (range) 26.4 (17.6–35.4)
Positive smoking history, n (%) 39 (57.4)
Comorbidities, n (%)
Cardiac 48 (70.6)
Respiratory 53 (77.9)
Metabolic 15 (22.1)
Lobe, n (%)
Right upper lobe 29 (42.6)
Right middle lobe 3 (4.4)
Right lower lobe 10 (14.7)
Left upper lobe 15 (22.1)
Left lower lobe 11 (16.1)
Location (distance from pleura), n (%)
Peripheral, outer third 32 (47.1)
Mid-lobar, middle third 20 (29.4)
Hilar inner third 16 (23.5)
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resolution after a short time without any treatment; no 
cancer cell seeding occurred in this series.
Discussion
The increased availability of CT with improved technology 
(such as sub-millimeter CT scan) has increased the 
detection rate of small pulmonary nodules, including 
early peripheral lung cancer (1,2). The recent diffusion 
of cancer screening programs makes the management of 
small pulmonary nodules a challenging issue. Furthermore, 
many more patients undergo screening autonomously. 
Finally, current targeting therapies require tissue sampling 
for molecular tests. Percutaneous fine needle biopsy of the 
lung has over the years become a simple, quick, safe and 
highly accurate procedure in the clinical management of 
patients with pulmonary lesions, especially the solitary ones. 
FNAB is an alternative to video-assisted thoracoscopic 
surgery in the diagnosis of solitary pulmonary nodules (17). 
Despite significant percentage of non-diagnostic results, 
FNAB technique is less invasive than VATS, avoids 
general anesthesia, and is associated with a lower rate of 
complications. Considering such characteristics, FNAB is 
usually suggested in high risk patients (3-8).
Several studies had fixed the FNAB overall sensitivity 
at 70–100% for the diagnosis of malignancy, and most 
reported values range from 85% to 95% (6-9,14-16,24,25). 
The same diagnosis could be obtained by endobronchial 
ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA) for peripheral lesions, with lower complication 
rate, but lower sensitivity as well (26); for this reason, we 
still consider EBUS-TBNA as the gold standard in case of 
nodal involvement (27), but not as the first choice in case of 
peripheral lung cancer.
The issue about the possible role of the dimensions of 
the pulmonary lesions in terms of sensitivity, diagnostic 
accuracy and rate of complications is still open (14). Ohno 
et al. reported a diagnostic accuracy of 52% for lesion size 
of 10 mm or less and 74.4% for lesion size ranging from 
11 to 15 mm (15). Wallace et al. reported an overall 
sensitivity and a diagnostic accuracy of 82% and 88% 
respectively in their series of FNAB of nodules ≤10 mm (16). 
In our study, the prevalence of adequate samples was 72%, 
a rate similar to Wallace (16). Interestingly, in our series 
the diagnostic accuracy for lesion size of 10 mm or less 
and for lesion size ranging from 11 to 15 mm was similar. 
It is well known that adequacy depends on the location, 
depth, diameter of the nodule and on the number of 
punctures; in addition, high cancer prevalence in a study 
population increases the adequacy (28). We consider 
adequacy prevalence over 70% a good reason for use FNAB 
as a suitable alternative to surgical biopsy in high risk 
patients. Nevertheless, the previous considerations should 
be carefully evaluated in every clinical case: an accurate 
selection of patients to submit to FNAB could potentially 
increase the adequacy up to 80%, as indicated by the upper 
limit of 95% confidence interval in our study.
Including inadequate findings in the accuracy calculation 
is a discussed matter; usually authors reporting FNAB 
on suspected breast lesions considered the inadequate 
results as malignant (29). From a clinical point of view, this 
behavior increases the indications to surgical biopsies, but 
it is obvious that surgical risk for pulmonary resection is 
considerable higher than breast surgery. Therefore, we don’t 
consider justified including inadequate samples as positive 
findings in the accuracy calculation, as well as in the clinical 
practice (19,20). On the other hand, some Authors included 
inadequate findings into negative results (28). Once again, 
we consider this assumption as a questionable clinical 
conduct: inadequate results should lead to repeat FNAB 
or consider further diagnostic strategy such as navigation 
bronchoscopy (30), surgical biopsy or close follow-up. From 
a methodological perspective, is it logical considering an 
inadequate finding a positive or negative result? According 
to other authors, we believe that inadequate samples can’t 
be included in the accuracy calculation (20,31,32).
In our experience about FNAB of small pulmonary 
lesions (≤15 mm), sensitivity and diagnostic accuracy value 
is considerable, especially if compared with the results on 
bigger nodules. This good result can be partially explained 
by analyzing the nature of the lesions in terms of CT 
appearance. Performing a biopsy of a small nodule is 
technically challenging, due to the difficulty in reaching the 
small target area. In the same way it is possible to state that 
biopsy in a large lesion is sometimes disheartening for the 
presence of a large necrotic area, which frequently leads to 
inadequate results. This consideration allows understanding 
how, although dealing with a small lesion is technically 
complicated, it often gets good results in terms of diagnostic 
accuracy.
During FNAB procedures, a cytopathologist should be 
present to reduce the number of non-conclusive specimens 
and decrease the number of recurrent biopsies (24,25,33-38). 
Moreover, in case of a malignant lesion, the cytopathologist 
can require an additional sample to be kept in formalin, in 
order to have sufficient material for immunohistochemical 
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studies (39-43). In addition, the use of CBs obtained from 
FNAB for the molecular testing of the tumor, is essential 
for the benefit of the patient, whose treatment may depend 
on the EGFR and ALK status (3,44). The discussion of the 
clinical case with the cytopathologist can help to guide the 
strategy for the biopsy: for example, in the case of suspected 
granulomatous pathology, or in case of difficult malignancies, 
is possible to perform a tru-cut biopsy for the confirmation 
of the diagnosis (45,46). Core-needle biopsies have high 
diagnostic yield, with an acceptable increased complication 
rate, but were not included in the present study (47). 
Although the estimated accuracy was extremely high in 
our study, its value must be cautiously considered: the lower 
limit of 95% CI indicates that, repeating the experience in a 
different scenario, the specificity and sensitivity should be at 
least 77% and 90%, respectively. Such values are similar to 
the performance obtained from the FNAB for larger SPNs. 
The intrinsic variability of FNAB could also be related to 
the pathological judgment. In this context, our selectiveness 
in determining sample adequacy and patients’ selection have 
led to a high diagnostic accuracy. 
Among the possible complications, pneumothorax is by 
far the most frequent; its reported rate ranges widely from 
22% to 45% (48-50). Cox et al. demonstrated, with a study 
about the variables that affected the risk of pneumothorax 
during FNAB, how the only variables that have proved 
to be statistically significant were the dimensions of the 
nodules and the evidence of emphysema (51). In a meta-
analysis published in 2017 by Heerink et al., smaller nodule 
diameter, larger needle diameter and increased traversed 
lung parenchyma were risk factors for complications (52). 
In our series the pneumothorax prevalence was similar to 
that reported in the literature; we found an association 
between the number of punctures and pneumothorax rate 
as reported by others (53).
The possibility of cancer cells seeding is well known as a 
potential risk of FNAB; we did not find any cancer seeding 
in our series but, although the incidence is quite rare, the 
seeding must be taken in account in the follow up (54).
Study limitations were related to the small sample size 
and to a possible selection bias.  
Conclusions
We believe that FNAB is a suitable tool for the diagnosis of 
lung nodule of 15 mm or less in high risk patients. Accurate 
patients’ selection, expert operator, rapid on-site evaluation 
and selectiveness in adequacy judgment are essential to 
reach high diagnostic accuracy that may avoid unnecessary 
surgical procedures. In fact, in our series, out of 49 patients 
who received adequate diagnosis, 14 (29%) of them resulted 
true negative and didn’t need surgical diagnosis.
In conclusion our study demonstrated that FNAB 
is an effective procedure even in the diagnosis of small 
pulmonary nodules. The accuracy resulted satisfactory 
while positive and negative predictive values reached the 
top rate. In the era of cancer screening and target medicine 
a diagnostic strategy including FNAB as the first approach 
to small pulmonary nodule in “sub-critical” patients should 
be revaluated. 
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